Zobrazeno 1 - 10
of 76
pro vyhledávání: '"G, Brenning"'
Autor:
Bo Nilsson, Håkan Mellstedt, Bengt Smedmyr, H. Gyllenhammar, Bertil Johansson, Richard A. Lerner, Anders Österborg, C. Paul, Gunnar Juliusson, H. Strander, C. Wedelin, Eva Kimby, B. Wadman, G. Brenning, A.-M. Stalfelt, Anders Ahre, G. Gahrton, Andreas Killander, Erik Svedmyr, Magnus Björkholm, Bengt Simonsson, M. Björeman, M. Järnmark, A.-M. Udén
Publikováno v:
European Journal of Haematology. 43:54-62
86 previously untreated patients with multiple myeloma stage III entered a randomized trial comparing combination chemotherapy (VMCP/VBAP) (n = 42) with intermittent oral melphalan and prednisone (MP) treatment (n = 44). The treatment gropus were wel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d569cf195418dd6be015ed13188ab7cd
https://doi.org/10.1111/j.1600-0609.1989.tb01252.x
https://doi.org/10.1111/j.1600-0609.1989.tb01252.x
Publikováno v:
European Journal of Haematology. 41:388-395
An unusual case of IgE-producing non-Hodgkin lymphoma (NHL) is presented. The patient's history included a 6-year period of increasing IgE level before a low grade NHL was diagnosed. The patient developed lymph node, skin, bone marrow and lung infilt
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b915d61da5835a229683b137b9891db
https://doi.org/10.1111/j.1600-0609.1988.tb00214.x
https://doi.org/10.1111/j.1600-0609.1988.tb00214.x
Autor:
Håkan Mellstedt, Gunnar Juliusson, Eva Ösby, Bengt Simonsson, Bengt Smedmyr, C. Paul, B. Wadman, Bertil Johansson, Erik Svedmyr, H. Strander, Magnus Björkholm, M. Björeman, H. Gyllenhammar, Andreas Killander, Karl Merk, G. Brenning, G. Grimfors, G. Gahrton, A.-M. Stalfelt, Eva Kimby, Richard A. Lerner, M. Järnmark, A.-M. Udén, Anders Österborg, R. Hast
Publikováno v:
European Journal of Haematology. 43:124-128
A randomized study comparing melphalan/prednisone (M/P) therapy with MP + natural alpha-IFN in untreated patients with multiple myeloma stages II and III started April 1, 1986. By March 1989, 78 patients were evaluable in the MP group and 80 in the M
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f5d65561e3fc0b7d41c6c86c06ff099e
https://doi.org/10.1111/j.1600-0609.1989.tb01504.x
https://doi.org/10.1111/j.1600-0609.1989.tb01504.x
Publikováno v:
Scandinavian Journal of Haematology. 35:543-549
26 of 32 patients with multiple myeloma (MM) were successfully tested in vitro for human leucocyte interferon (IFN) sensitivity by use of the human tumour stem cell assay (HTCA) and/or 3H-thymidine incorporation (LI). Altogether, 12 patients were sen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e1f6c9ed40c4520b87123f9d7755b60f
https://doi.org/10.1111/j.1600-0609.1985.tb02826.x
https://doi.org/10.1111/j.1600-0609.1985.tb02826.x
Publikováno v:
Lakartidningen. 91(36)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::ee0b020da48179b06e2501938a6e992c
https://pubmed.ncbi.nlm.nih.gov/7990565
https://pubmed.ncbi.nlm.nih.gov/7990565
Autor:
M. Järnmark, H. Gyllenhammar, A.-M. Udén, Bengt Smedmyr, G. Brenning, Kristina Carlson, Astrid Gruber, M. Ohrling, R. Hast, C. Paul, Anders Österborg, Fredrik Celsing, G. Gahrton, Bengt Simonsson, Eva Kimby, Olle Linder, Bertil Johansson, Gunnar Juliusson, Richard A. Lerner, M. Björeman, Karl Merk, Håkan Mellstedt, Eva Ösby, Erik Svedmyr, Magnus Björkholm, A.-M. Stalfelt, G. Grimfors
Publikováno v:
European journal of haematology. 51(1)
Fifty-six patients with refractory multiple myeloma were treated with intermittent courses of etoposide, doxorubicin, cyclophosphamide and high-dose betamethasone (EACB) every 4th week. The overall response rate was 30%. Durable remissions exceeding
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::235ded88f3aa071a7191dd011072e0e3
https://pubmed.ncbi.nlm.nih.gov/8348944
https://pubmed.ncbi.nlm.nih.gov/8348944
Autor:
Fredrik Celsing, G. Grimfors, Magnus Björkholm, Kristina Carlson, Robert Hast, Mats Björeman, H. Gyllenhammar, G. Brenning, G. Gahrton, Anders Österborg
Publikováno v:
Blood. 81(6)
Three hundred thirty-five previously untreated patients with multiple myeloma in clinical stages II and III entered a randomized trial comparing intermittent oral melphalan and prednisone (MP) therapy (n = 171) with MP in combination with natural (le
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1e0ee3033b74a3ae0a6b2219bc7c4e10
https://pubmed.ncbi.nlm.nih.gov/8453092
https://pubmed.ncbi.nlm.nih.gov/8453092
Autor:
Robert Hast, A.-M. Stalfelt, B. Johansson, Christer Paul, A. Killander, Gunnar Juliusson, M. Björeman, Håkan Mellstedt, G. Gahrton, G. Brenning, B. Simonsson, E. Svedmyr, B. Smedmyr, Eva Ösby, Magnus Björkholm, M. Järnmark, A.-M. Udén, A. Åhre, Bo Nilsson, B. Wadman, Anders Österborg, Eva Kimby, Gunnar Grimfors, R. Lerner, H. Gyllenhammar
Publikováno v:
Acta oncologica (Stockholm, Sweden). 29(6)
Eighty-one previously untreated patients with multiple myeloma stage II entered a randomized trial comparing oral melphalan (0.25 mg/kg/day; n = 40) with intravenous melphalan (0.125 mg/kg/day; n = 41) in combination with oral prednisone (2 mg/kg/day
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8309d3b6d3d368815820841eab9d7d99
https://pubmed.ncbi.nlm.nih.gov/2223143
https://pubmed.ncbi.nlm.nih.gov/2223143
Autor:
J. S. Gronowitz, G. Brenning, A. Åhre, Andreas Killander, Clas Källander, R. Bergstrom, Bengt Simonsson
Publikováno v:
British Journal of Haematology. 69:47-53
The analysis of individual biochemical and clinical variables in 121 patients with multiple myeloma showed that serum beta 2-microglobulin (S-beta 2m) had the most significant relation to survival. Other variables such as serum thymidine kinase (S-TK
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::509154af97191dc77c2998639148a2d3
https://doi.org/10.1111/j.1365-2141.1988.tb07601.x
https://doi.org/10.1111/j.1365-2141.1988.tb07601.x
Publikováno v:
European Journal of Haematology. 37:280-288
An IFN-resistant subline (U-266r alpha) was established from the IFN-alpha-sensitive myeloma cell line U-266 by subculturing U-266 cells with increasing doses of INF-alpha. The U-266r alpha secreted IgE at a higher rate than the U-266 (7.2 X 10(-13)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::59989a4a3494d2462537ede1744df3ae
https://doi.org/10.1111/j.1600-0609.1986.tb02313.x
https://doi.org/10.1111/j.1600-0609.1986.tb02313.x